Latest Clinical Trials
Studies have revealed that obesity is a significant risk factor for the development of cholangiocarcinoma.
Genomic profiling for cholangiocarcinoma and other cancers demonstrates significant evidence-based benefits, but faces practical hurdles.
Over the last decade, medical research has led to significant progress in the diagnosis and treatment of perihilar cholangiocarcinoma.
Disease progression has a major impact on outcomes in patients with intrahepatic cholangiocarcinoma and many factors influence recurrence-free survival, studies have found.
Many are heralding radiomics as the “next big thing” that will revolutionize medicine. We examine this claim, particularly when it comes to cholangiocarcinoma treatment.
Researchers explain the specific challenges of diagnosing and managing iCCA, and why a multidisciplinary approach works best.
We explore the risk factors associated with the various subtypes of cholangiocarcinoma and discuss their reliability.
When 2 friends set out along Spain’s 500-mile Camino de Santiago, they didn’t know how many people they’d inspire with 3 little words: “I’ll Push You.”
A confusing system of disease codes has led to inaccurate reporting of the number of cholangiocarcinoma cases worldwide, a renowned liver specialist said.
Dr. Reham Abdel-Wahab of the Cholangiocarcinoma Foundation says a raft of FDA-approved therapies and ongoing clinical trials will expand treatment options.
Eliminating geographic and ethnic bias in clinical trials for rare diseases is the goal of Jeeva Informatics, says founder and CEO Harsha K. Rajasimha, PhD.
Rare Care Podcast